| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.86(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
766,409 |
1,189,266 |
1,315,394 |
1,951,649 |
| Total Sell Value |
$6,577,948 |
$9,083,370 |
$9,535,666 |
$10,165,404 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
59 |
102 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-08-21 |
4 |
S |
$3.55 |
$3,328 |
I/I |
(937) |
111,225 |
|
-79% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-08-21 |
4 |
S |
$3.55 |
$10,108 |
D/D |
(2,846) |
369,919 |
|
-79% |
|
| Felsch Robert Ora |
See Remarks |
• – – |
2023-08-21 |
4 |
S |
$3.55 |
$3,722 |
D/D |
(1,048) |
115,110 |
|
-79% |
|
| Blanks Robert |
See Remarks |
• – – |
2023-08-21 |
4 |
S |
$3.55 |
$10,108 |
D/D |
(2,846) |
263,288 |
|
-79% |
|
| Raab Michael |
President & CEO |
• • – |
2023-08-21 |
4 |
S |
$3.55 |
$40,558 |
D/D |
(11,419) |
876,236 |
|
-79% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2023-06-27 |
4 |
S |
$3.35 |
$83,633 |
D/D |
(25,000) |
294,430 |
|
-19% |
|
| Blanks Robert |
See Remarks |
• – – |
2023-06-23 |
4 |
AS |
$3.63 |
$121,042 |
D/D |
(33,333) |
266,134 |
|
10% |
|
| Blanks Robert |
See Remarks |
• – – |
2023-06-23 |
4 |
OE |
$3.42 |
$113,999 |
D/D |
33,333 |
299,467 |
|
- |
|
| Bertrand William C Jr |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,581 |
218,743 |
|
- |
|
| Lundberg Jan M |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,755 |
146,794 |
|
- |
|
| Cadoret-Manier Onaiza |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,755 |
110,150 |
|
- |
|
| Mott David M |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
25,510 |
1,192,275 |
|
- |
|
| Rodgers Richard J |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
18,494 |
238,320 |
|
- |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2023-05-23 |
4 |
S |
$3.65 |
$10,496 |
D/D |
(2,873) |
336,733 |
|
-14% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2023-05-23 |
4 |
S |
$3.65 |
$8,709 |
D/D |
(2,384) |
330,451 |
|
-14% |
|
| Blanks Robert |
See Remarks |
• – – |
2023-05-23 |
4 |
S |
$3.65 |
$10,357 |
D/D |
(2,835) |
266,134 |
|
-14% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-05-23 |
4 |
S |
$3.65 |
$3,412 |
I/I |
(934) |
112,162 |
|
-14% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-05-23 |
4 |
S |
$3.65 |
$10,357 |
D/D |
(2,835) |
372,765 |
|
-14% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2023-05-23 |
4 |
S |
$3.65 |
$9,436 |
D/D |
(2,583) |
319,430 |
|
-14% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2023-05-23 |
4 |
S |
$3.65 |
$17,210 |
D/D |
(4,711) |
353,420 |
|
-14% |
|
| Felsch Robert Ora |
See Remarks |
• – – |
2023-05-23 |
4 |
S |
$3.65 |
$3,821 |
D/D |
(1,046) |
116,158 |
|
-14% |
|
| Raab Michael |
President & CEO |
• • – |
2023-05-23 |
4 |
S |
$3.65 |
$41,489 |
D/D |
(11,357) |
887,655 |
|
-14% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2023-02-21 |
4 |
S |
$3.00 |
$16,764 |
D/D |
(5,586) |
355,131 |
|
-15% |
|
| Felsch Robert Ora |
See Remarks |
• – – |
2023-02-21 |
4 |
S |
$3.00 |
$9,645 |
D/D |
(3,214) |
114,204 |
|
-15% |
|
| Blanks Robert |
See Remarks |
• – – |
2023-02-21 |
4 |
S |
$3.00 |
$10,185 |
D/D |
(3,394) |
268,969 |
|
-15% |
|
538 Records found
|
|
Page 3 of 22 |
|
|
0.25 (3.22%) 
